B. Metzler seel. Sohn & Co. Holding AG Purchases Shares of 31,366 AtriCure, Inc. (NASDAQ:ATRC)

B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 31,366 shares of the medical device company's stock, valued at approximately $880,000. B. Metzler seel. Sohn & Co. Holding AG owned about 0.06% of AtriCure as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. First Light Asset Management LLC raised its position in AtriCure by 42.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,964,703 shares of the medical device company's stock worth $44,736,000 after buying an additional 581,843 shares during the last quarter. Hood River Capital Management LLC purchased a new position in AtriCure during the second quarter worth about $40,422,000. Millennium Management LLC lifted its position in AtriCure by 132.5% in the second quarter. Millennium Management LLC now owns 952,765 shares of the medical device company's stock valued at $21,694,000 after purchasing an additional 543,023 shares during the period. Fiera Capital Corp boosted its holdings in AtriCure by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 918,207 shares of the medical device company's stock valued at $20,908,000 after purchasing an additional 10,432 shares in the last quarter. Finally, Emerald Advisers LLC increased its position in AtriCure by 10.9% during the 3rd quarter. Emerald Advisers LLC now owns 389,836 shares of the medical device company's stock worth $10,931,000 after purchasing an additional 38,421 shares during the period. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Trading Up 0.2 %

Shares of NASDAQ:ATRC traded up $0.05 during trading on Friday, reaching $35.74. The stock had a trading volume of 459,821 shares, compared to its average volume of 741,642. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $42.99. The business has a fifty day moving average price of $30.93 and a 200-day moving average price of $25.90. The stock has a market cap of $1.74 billion, a P/E ratio of -43.05 and a beta of 1.41. The company has a quick ratio of 2.59, a current ratio of 3.62 and a debt-to-equity ratio of 0.13.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. The company had revenue of $115.91 million for the quarter, compared to analyst estimates of $112.23 million. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. The business's revenue for the quarter was up 17.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.20) EPS. As a group, analysts anticipate that AtriCure, Inc. will post -0.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. UBS Group increased their price objective on AtriCure from $35.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Needham & Company LLC increased their target price on shares of AtriCure from $34.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Oppenheimer boosted their target price on AtriCure from $32.00 to $36.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Piper Sandler cut their price target on AtriCure from $65.00 to $40.00 and set an "overweight" rating for the company in a research note on Wednesday, July 31st. Finally, Canaccord Genuity Group increased their price objective on shares of AtriCure from $49.00 to $53.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, AtriCure has a consensus rating of "Moderate Buy" and an average target price of $43.11.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.